MA46203A - Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase - Google Patents
Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydaseInfo
- Publication number
- MA46203A MA46203A MA046203A MA46203A MA46203A MA 46203 A MA46203 A MA 46203A MA 046203 A MA046203 A MA 046203A MA 46203 A MA46203 A MA 46203A MA 46203 A MA46203 A MA 46203A
- Authority
- MA
- Morocco
- Prior art keywords
- homologue
- inhibitor
- oxydase
- lysyl
- lysyl oxydase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662384542P | 2016-09-07 | 2016-09-07 | |
US201762509460P | 2017-05-22 | 2017-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46203A true MA46203A (fr) | 2019-07-17 |
Family
ID=61561650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046203A MA46203A (fr) | 2016-09-07 | 2017-09-06 | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
Country Status (12)
Country | Link |
---|---|
US (2) | US11793797B2 (fr) |
EP (2) | EP3509594A4 (fr) |
JP (1) | JP7097874B2 (fr) |
KR (2) | KR20230162996A (fr) |
CN (2) | CN117180280A (fr) |
AU (1) | AU2017324444A1 (fr) |
BR (1) | BR112019004513A2 (fr) |
CA (1) | CA3036062A1 (fr) |
IL (1) | IL265232A (fr) |
MA (1) | MA46203A (fr) |
MX (1) | MX2019002612A (fr) |
WO (1) | WO2018048942A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016144702A1 (fr) * | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
SG11201707246YA (en) | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
EP3414229B1 (fr) | 2016-02-09 | 2021-06-16 | Pharmakea, Inc. | Inhibiteurs quinolinone de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
EP3509594A4 (fr) | 2016-09-07 | 2020-05-06 | Pharmakea, Inc. | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
CN112441916A (zh) * | 2019-08-29 | 2021-03-05 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
JP2022548725A (ja) * | 2019-09-20 | 2022-11-21 | レネオ ファーマシューティカルズ,インク. | 腎臓病の治療におけるpparデルタアゴニストの使用 |
CN110714016B (zh) * | 2019-11-29 | 2021-08-20 | 长沙学院 | Jnk基因及其作为鱼类细菌性肠炎诊断分子标记物和治疗靶点的应用 |
CN112662763A (zh) * | 2020-03-10 | 2021-04-16 | 博尔诚(北京)科技有限公司 | 一种检测常见两性癌症的探针组合物 |
WO2023196963A1 (fr) * | 2022-04-08 | 2023-10-12 | The Regents Of The University Of California | Traitement métabolique-épigénétique combiné pour le cancer du poumon précoce |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5250532A (en) | 1991-04-11 | 1993-10-05 | Dowelanco | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides |
US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
HUP0204272A3 (en) | 2000-01-18 | 2005-03-29 | Pfizer Prod Inc | Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
EP1638551B1 (fr) | 2003-05-19 | 2011-12-21 | Irm Llc | Composes immunosuppresseurs et compositions |
BRPI0507250A (pt) | 2004-01-29 | 2007-06-26 | Pfizer Prod Inc | combinações para tratar desordens do snc |
US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
EP1735268B1 (fr) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Antagonistes des recepteurs opioides |
MXPA06012333A (es) | 2004-04-30 | 2007-01-17 | Takeda Pharmaceutical | Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13. |
US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
MX2007002842A (es) | 2004-09-10 | 2007-04-30 | Pfizer Prod Inc | Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol. |
JP2008512440A (ja) | 2004-09-10 | 2008-04-24 | ファイザー・プロダクツ・インク | ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法 |
WO2006052546A2 (fr) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Dérivés hétéroaryles de pyrazolylméthyle |
DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
CA2593858A1 (fr) | 2005-01-31 | 2006-08-10 | Min Ge | Composes bicycliques antidiabetiques |
AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
EP1915369A4 (fr) | 2005-08-11 | 2010-09-08 | Merck Frosst Canada Ltd | Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
ITMI20051943A1 (it) | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
JP2009523820A (ja) | 2006-01-23 | 2009-06-25 | アミラ ファーマシューティカルス,インコーポレーテッド | 5−リポキシゲナーゼの三環系抑制剤 |
GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
EP2121703A4 (fr) | 2006-08-18 | 2011-12-28 | Astrazeneca Ab | Dérivés de thiénopyrimidin-4-one et de thiénopyridazin-7-one en tant qu'antagonistes du mch rl |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
EP2537529B1 (fr) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Anticorps inhibiteurs dirigés contre loxl2, et procédés d'utilisation associés |
MX2012001156A (es) | 2009-07-28 | 2012-05-08 | Anacor Pharmaceuticals Inc | Moleculas que contienen boro trisustituidas. |
JP2013502437A (ja) | 2009-08-21 | 2013-01-24 | ギリアド バイオロジクス,インク. | 治療方法及び組成物 |
CN103370080A (zh) * | 2010-02-04 | 2013-10-23 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
JP2013518909A (ja) | 2010-02-08 | 2013-05-23 | キナゲン,インク. | アロステリックキナーゼ阻害が関係する治療方法および組成物 |
CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
WO2011150201A2 (fr) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Composés azolylamide et leurs procédés d'utilisation |
EP2441755A1 (fr) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK |
WO2012068450A1 (fr) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Dérivés pyrrolopyridine et pyrrolopyrimidine à substitution cyclobutyle utilisés comme inhibiteurs des jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
AU2012325909B2 (en) | 2011-10-20 | 2016-06-09 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
RU2632899C2 (ru) | 2012-04-25 | 2017-10-11 | Раквалиа Фарма Инк. | Амидопроизводные как блокаторы ttx-s |
US20140120102A1 (en) * | 2012-10-30 | 2014-05-01 | Gilead Sciences, Inc. | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
CN104854086B (zh) | 2012-12-18 | 2017-06-27 | Ea制药株式会社 | 杂环酰胺衍生物和含有其的药物 |
WO2016020732A1 (fr) | 2014-08-05 | 2016-02-11 | The University Of British Columbia | Modulateurs de caspase 6 |
US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
SG11201706451TA (en) | 2015-02-15 | 2017-09-28 | Hoffmann La Roche | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
SG11201707246YA (en) * | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
WO2016144702A1 (fr) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
EP3509594A4 (fr) | 2016-09-07 | 2020-05-06 | Pharmakea, Inc. | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
-
2017
- 2017-09-06 EP EP17849478.7A patent/EP3509594A4/fr active Pending
- 2017-09-06 JP JP2019512639A patent/JP7097874B2/ja active Active
- 2017-09-06 CA CA3036062A patent/CA3036062A1/fr active Pending
- 2017-09-06 WO PCT/US2017/050331 patent/WO2018048942A1/fr unknown
- 2017-09-06 BR BR112019004513A patent/BR112019004513A2/pt unknown
- 2017-09-06 CN CN202311201078.5A patent/CN117180280A/zh active Pending
- 2017-09-06 CN CN201780068871.9A patent/CN109922803B/zh active Active
- 2017-09-06 KR KR1020237039437A patent/KR20230162996A/ko active Application Filing
- 2017-09-06 MX MX2019002612A patent/MX2019002612A/es unknown
- 2017-09-06 US US16/331,082 patent/US11793797B2/en active Active
- 2017-09-06 EP EP22168167.9A patent/EP4052707A1/fr active Pending
- 2017-09-06 MA MA046203A patent/MA46203A/fr unknown
- 2017-09-06 KR KR1020197009467A patent/KR102615565B1/ko active IP Right Grant
- 2017-09-06 AU AU2017324444A patent/AU2017324444A1/en not_active Abandoned
-
2019
- 2019-03-06 IL IL265232A patent/IL265232A/en unknown
-
2021
- 2021-02-03 US US17/166,689 patent/US20210177820A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11793797B2 (en) | 2023-10-24 |
US20190192495A1 (en) | 2019-06-27 |
KR102615565B1 (ko) | 2023-12-18 |
US20210177820A1 (en) | 2021-06-17 |
JP7097874B2 (ja) | 2022-07-08 |
BR112019004513A2 (pt) | 2019-06-18 |
KR20230162996A (ko) | 2023-11-29 |
CN117180280A (zh) | 2023-12-08 |
CN109922803B (zh) | 2023-09-22 |
KR20190065265A (ko) | 2019-06-11 |
IL265232A (en) | 2019-05-30 |
EP4052707A1 (fr) | 2022-09-07 |
WO2018048942A1 (fr) | 2018-03-15 |
MX2019002612A (es) | 2019-08-21 |
EP3509594A1 (fr) | 2019-07-17 |
CA3036062A1 (fr) | 2018-03-15 |
AU2017324444A1 (en) | 2019-04-11 |
EP3509594A4 (fr) | 2020-05-06 |
CN109922803A (zh) | 2019-06-21 |
JP2019526589A (ja) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46203A (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
MA49047A (fr) | Composés inhibiteurs d'ask1 et utilisations associées | |
DK3601283T3 (da) | Kondenseret imidazo-piperidin-JAK-inhibitorforbindelse | |
DK3668855T3 (da) | Herbicide forbindelser | |
DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
MA42606A (fr) | Sels d'un inhibiteur de lsd1 | |
MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
MA51616A (fr) | Inhibiteurs d'adn-pk | |
MA47573A (fr) | Inhibiteurs de dihydrobenzofurane glycosidase substitués | |
DK3533796T3 (da) | Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor | |
MA41350A (fr) | Synthèse d'un inhibiteur de la tyrosine kinase de bruton | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA47420A (fr) | Composés inhibiteurs d'oga | |
MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
DK3668955T3 (da) | Korrosionsinhibitor | |
MA46589A (fr) | Composés et utilisations de ces derniers | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
MA54901A (fr) | Inhibiteur de 15-pgdh | |
DK3562487T3 (da) | Metalloenzyminhibitorforbindelser | |
MA50906A (fr) | Inhibiteurs d'immunoprotéasome | |
MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase |